copeptin
Copeptin is a 39-amino acid-long peptide derived from the C-terminus of pre-pro-hormone of arginine vasopressin, neurophysin II and copeptin. Arginine vasopressin (AVP), also known as the antidiuretic hormone (ADH), is encoded by the AVP gene and is involved in multiple cardiovascular and renal pathways and abnormal level of AVP are associated with various diseases. Hence measurement of AVP would be useful, but is not commonly carried out in clinical practice because of its very short half-life making it difficult to quantify. In contrast, copeptin can be immunologically tested with ease and therefore can be used as a vasopressin surrogate marker. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Mar 31, 2011 (NCT01334645)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCopeptin ↗
Also known as
- copeptin
- copeptin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03536910 | N/A | May 1, 2018 | Istanbul University |
| NCT01960478 | N/A | Oct 1, 2013 | University of Strasbourg |
| NCT01334645 | N/A | Mar 31, 2011 | University Clermont Auvergne |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Istanbul University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University Clermont Auvergne | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Strasbourg | Academic/Hospital | 1 | 1 | 1 | 2013 |